AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psori…
Drug Manufacturers - General
US, North Chicago [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
1
Financial Health
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Current Ratio | 7.34 | 0.94 | 0.87 | |
| Debt/Assets | n.A. | n.A. | n.A. | |
| Debt/Equity | n.A. | n.A. | n.A. | |
| Net Debt/EBITDA | -0.77 | 11.05 | 11.13 | |
| Naive Interpretation | member | |||
2
Per Share
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | -22.85 | 4.53 | 5.87 | |
| Cash | 40.74 | 10.21 | 7.26 | |
| Capex | 6.02 | -0.11 | -0.12 | |
| Free Cash Flow | -15.56 | 2.17 | 2.58 | |
| Revenue | -14.07 | 6.96 | 8.10 | |
| Naive Interpretation | member | |||
3
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Margin | -19.78 | 0.67 | 0.83 | |
| Operating Margin | -22.82 | 0.24 | 0.31 | |
| ROA | 50.70 | < 0.005 | < 0.005 | |
| ROE | 115.49 | 0.17 | 0.08 | |
| ROIC | -35.03 | 0.03 | 0.04 | |
| Naive Interpretation | member | |||
4
Valuation
The "Valuation Entry" for the Focus of ABBV is permitted for members.
5
Growth
The "Growth Entry" for the Focus of ABBV is permitted for members.
6
Leverage & Liquidity